button bars forest bayes pooled summary circles
benefit
(statisticaly significant) 		benefit (nominaly significant, not statitically demonstrated) NS not significant harm statitically significant NS harm not significant low certainty due to bias
 
deaths (OS)progression or deaths (PFS)RFS/DFS

mML - NA - all population metastatic/adv melanoma (mML) mML - (neo)adjuvant (NA) mML - NA - all population

versus Ipilimumab (10 mg/kg)
nivolumab alone vs. Ipilimumab (10 mg/kg) 1 NS--35%
versus placebo
nivolumab alone vs. placebo 1 ---44%

mML - NA - PDL1 positive metastatic/adv melanoma (mML) mML - (neo)adjuvant (NA) mML - NA - PDL1 positive

mML - L1 - all population metastatic/adv melanoma (mML) mML - 1st line (L1) mML - L1 - all population

versus ipilimumab alone
nivolumab alone vs. ipilimumab alone 1 -37%-43%-

mML - L1 - BRAF mutant metastatic/adv melanoma (mML) mML - 1st line (L1) mML - L1 - BRAF mutant

mML - L1 - BRAF wild metastatic/adv melanoma (mML) mML - 1st line (L1) mML - L1 - BRAF wild

versus dacarbazine
nivolumab alone vs. dacarbazine 1 -58%-57%-

mML - L2 - all population metastatic/adv melanoma (mML) mML - 2nd line (L2) mML - L2 - all population

versus Standard of Care (SoC)
nivolumab alone vs. Standard of Care (SoC) 1 NSNS-

mML - L2 - BRAF mutant metastatic/adv melanoma (mML) mML - 2nd line (L2) mML - L2 - BRAF mutant

 

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons